Literature DB >> 9520015

Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor.

V de la Sayette1, F Bertran, J Honnorat, S Schaeffer, S Iglesias, G Defer.   

Abstract

OBJECTIVE: To describe a patient with a paraneoplastic cerebellar syndrome and optic neuritis with circulating anti-CV2 antibodies and clinical improvement after excision of a small cell lung carcinoma.
DESIGN: Report of a case.
SETTING: A 62-year-old man simultaneously developed a severe cerebellar syndrome and a bilateral optic neuritis predominantly in the left eye (visual acuity, 20/25 in the right eye; < 20/400 in the left eye; and bilateral swelling of the optic discs). MAIN OUTCOME AND
RESULTS: Anti-CV2 antibodies, recently described as associated with paraneoplastic neurological syndrome, were detected in the patient's serum sample. These antibodies were demonstrated to react with the cytoplasm of a subpopulation of oligodendrocytes in the white matter of rat brain in the cerebellum, brainstem, spinal cord, and optic chiasm. The patient was found to have a small cell lung carcinoma, which was removed. After excision of the tumor, the cerebellar syndrome improved dramatically and the papilledema disappeared despite aftereffects of the optic neuritis.
CONCLUSIONS: These findings were consistent with the diagnosis of a paraneoplastic neurological syndrome, although both optic neuritis and remission of the cerebellar syndrome are uncommon patterns of paraneoplastic syndromes. CV2 antigen expression by the oligodendrocytes of the cerebellum, brainstem, spinal cord, and optic chiasm correlated with the clinical syndrome observed in our patient. However, the precise pathophysiological role of anti-CV2 antibodies is still unknown.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9520015     DOI: 10.1001/archneur.55.3.405

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  12 in total

Review 1.  Anti-CV2 autoantibodies and paraneoplastic neurological syndromes.

Authors:  V Rogemond; J Honnorat
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

2.  A follow up study of patients with paraneoplastic neurological disease in the United Kingdom.

Authors:  P M Candler; P E Hart; M Barnett; R Weil; J H Rees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

3.  Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies.

Authors:  Adrián Arés-Luque; L A García-Tuñón; A Saiz; B C Cabezas; L E Hernández-Echebarría; M Franco; A Toribio; J Tejada; F Graus
Journal:  J Neurol       Date:  2007-04-02       Impact factor: 4.849

4.  Paraneoplastic neurological syndromes: general treatment overview.

Authors:  Aurélien Viaccoz; Jérôme Honnorat
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

5.  Small cell lung cancer and progressive retinopathy.

Authors:  Mami Morita; Tatsuro Fukuhara; Hidetoshi Takahashi; Makoto Maemondo
Journal:  BMJ Case Rep       Date:  2014-11-24

6.  Anti-Collapsing Response-Mediating Protein-5 Antibody-Positive Paraneoplastic Perioptic Neuritis without Typical Neurological Symptoms.

Authors:  Nozomi Igarashi; Hiromasa Sawamura; Toshikatsu Kaburaki; Makoto Aihara
Journal:  Neuroophthalmology       Date:  2016-10-27

Review 7.  Optic neuropathy in cancer patients. Report of a case possibly related to 5 fluorouracil toxicity and review of the literature.

Authors:  L Delval; J Klastersky
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

8.  Acute Management of Optic Neuritis: An Evolving Paradigm.

Authors:  Lindsay Horton; Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2018-09       Impact factor: 3.042

9.  Paraneoplastic Retinopathy/Optic Neuropathy.

Authors:  Denise M Damek
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

10.  Successful treatment of cancer-associated retinopathy with alemtuzumab.

Authors:  Ladan Espandar; Susan O'Brien; Charles Thirkill; Linda A Lubecki; Bita Esmaeli
Journal:  J Neurooncol       Date:  2007-01-25       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.